Skip to main content
BIIB
NASDAQ Life Sciences

Biogen's Diranersen Phase 2 Alzheimer's Study Shows Cognitive Benefit, Misses Primary Endpoint

Tom Rudovsky · Reported by Reuters
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Neutral
Importance info
8
Price
$215
Mkt Cap
$30.196B
52W Low
$119.18
52W High
$205.97
52W Position info
80% above low
Off High info
at 52W high
Rel. Volume info
1.1× avg
Market data snapshot near publication time

BIIB sits 80% above its 52-week low of $119.18.

Summary

Biogen announced mixed topline results from its Phase 2 Celia study of Diranersen (BIIB080) for early Alzheimer's Disease. The study showed a robust reduction in tau pathology and a slowing of clinical decline across all doses, with a safety profile consistent with previous studies. However, the study notably did not meet its primary endpoint for dose response on the CDR-SB scale at week 76. These mixed efficacy signals present a complex picture for investors, as positive biological and cognitive trends are offset by the failure to meet the primary statistical endpoint. This news is highly material for Biogen, a major player in neuroscience, and will prompt close scrutiny of the company's strategic decisions regarding Diranersen's future development.

At the time of this announcement, BIIB was trading at $215.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $30.2B. The 52-week trading range was $119.18 to $205.97. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Reuters.


Price Chart

Share this article

Copied!

BIIB - Latest Insights

BIIB
Nov 09, 2026, 1:02 AM EST
Source: Reuters
Importance Score:
8
Price at Filing: $248.35
Real-time Price: $253.40 info
Change: +$5.05 (+2%) info
Market Cap: $37.458B info
BIIB
Oct 28, 2026, 6:23 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $252.73
Real-time Price: $253.40 info
Change: +$0.670 (+0.27%) info
Market Cap: $37.458B info
BIIB
Oct 28, 2026, 6:07 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $252.73
Real-time Price: $253.40 info
Change: +$0.670 (+0.27%) info
Market Cap: $37.458B info
BIIB
Oct 28, 2026, 6:00 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $252.73
Real-time Price: $253.40 info
Change: +$0.670 (+0.27%) info
Market Cap: $37.458B info
BIIB
Oct 02, 2026, 11:20 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $221.12
Real-time Price: $253.40 info
Change: +$32.28 (+15%) info
Market Cap: $37.458B info